{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:33:51Z","timestamp":1787009631361,"version":"build-2736575974"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,6,2]],"date-time":"2018-06-02T00:00:00Z","timestamp":1527897600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ardea Biosciences\/AstraZeneca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1093\/rheumatology\/key100","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T02:56:35Z","timestamp":1523501795000},"page":"1602-1610","source":"Crossref","is-referenced-by-count":33,"title":["Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study"],"prefix":"10.1093","volume":"57","author":[{"given":"Masanari","family":"Shiramoto","sequence":"first","affiliation":[{"name":"SOUSEIKAI PS Clinic, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Liu","sequence":"additional","affiliation":[{"name":"Ardea Biosciences, Inc., San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zancong","family":"Shen","sequence":"additional","affiliation":[{"name":"Ardea Biosciences, Inc., San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Yan","sequence":"additional","affiliation":[{"name":"Ardea Biosciences, Inc., San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Ardea Biosciences, Inc., San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gillen","sequence":"additional","affiliation":[{"name":"AstraZeneca LP, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Ito","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Hall","sequence":"additional","affiliation":[{"name":"Ardea Biosciences, Inc., San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"key\n\t\t\t\t20180823035348_key100-B1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/BOR.0000000000000028","article-title":"Definition of hyperuricemia and gouty conditions","volume":"26","author":"Bardin","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"key\n\t\t\t\t20180823035348_key100-B2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12325-014-0175-z","article-title":"A review of uric acid, crystal deposition disease, and gout","volume":"32","author":"Perez-Ruiz","year":"2015","journal-title":"Adv Ther"},{"key":"key\n\t\t\t\t20180823035348_key100-B3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrrheum.2014.32","article-title":"Optimizing current treatment of gout","volume":"10","author":"Rees","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"key\n\t\t\t\t20180823035348_key100-B4","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.2174\/1381612811319130011","article-title":"Chronic hyperuricemia, uric acid deposit and cardiovascular risk","volume":"19","author":"Grassi","year":"2013","journal-title":"Curr Pharm Des"},{"key":"key\n\t\t\t\t20180823035348_key100-B5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrrheum.2014.124","article-title":"Improving cardiovascular and renal outcomes in gout: what should we target?","volume":"10","author":"Richette","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"key\n\t\t\t\t20180823035348_key100-B6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11906-013-0344-5","article-title":"Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal?","volume":"15","author":"Soltani","year":"2013","journal-title":"Curr Hypertens Rep"},{"key":"key\n\t\t\t\t20180823035348_key100-B7","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","article-title":"Gout: why is this curable disease so seldom cured?","volume":"71","author":"Doherty","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180823035348_key100-B8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1477-7525-10-117","article-title":"Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey","volume":"10","author":"Khanna","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"key\n\t\t\t\t20180823035348_key100-B9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180823035348_key100-B10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","article-title":"An open-label, 6-month study of allopurinol safety in gout: the LASSO study","volume":"45","author":"Becker","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t20180823035348_key100-B11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13075-015-0624-3","article-title":"Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort","volume":"17","author":"Singh","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180823035348_key100-B12","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t20180823035348_key100-B13","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","article-title":"Japanese guideline for the management of hyperuricemia and gout: second edition","volume":"30","author":"Yamanaka","year":"2011","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"key\n\t\t\t\t20180823035348_key100-B14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/2040622312462056","article-title":"Latest evidence on gout management: what the clinician needs to know","volume":"3","author":"Burns","year":"2012","journal-title":"Ther Adv Chronic Dis"},{"key":"key\n\t\t\t\t20180823035348_key100-B15","volume-title":"Guideline for the Management of Hyperuricemia and Gout","author":"Nakamura","year":"2003"},{"key":"key\n\t\t\t\t20180823035348_key100-B16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180823035348_key100-B17","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: a phase III clinical trial","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180823035348_key100-B18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180823035348_key100-B19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/annrheumdis-2012-202594","article-title":"Gout treatment: should we aim for rapid crystal dissolution?","volume":"72","author":"Pascual","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180823035348_key100-B20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180823035348_key100-B21","first-page":"ii9","article-title":"Treating to target: a strategy to cure gout","volume":"48(Suppl 2)","author":"Perez-Ruiz","year":"2009","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180823035348_key100-B22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/03007995.2016.1239193","article-title":"Serum uric acid levels and the risk of flares among gout patients in a US managed care setting","volume":"33","author":"Shiozawa","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"key\n\t\t\t\t20180823035348_key100-B23","article-title":"The safety and efficacy of lower serum urate levels: a pooled analysis of gout subjects receiving lesinurad and xanthine oxidase inhibitors [abstract]","volume":"67(Suppl 10)","author":"Terkeltaub","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180823035348_key100-B24","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41598-017-00706-7","article-title":"Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout","volume":"7","author":"Tan","year":"2017","journal-title":"Sci Rep"},{"key":"key\n\t\t\t\t20180823035348_key100-B25","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.2147\/DDDT.S140658","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects","volume":"11","author":"Shen","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"key\n\t\t\t\t20180823035348_key100-B26","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.2147\/DDDT.S152659","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects","volume":"12","author":"Hall","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"key\n\t\t\t\t20180823035348_key100-B27","doi-asserted-by":"crossref","first-page":"e000584","DOI":"10.1136\/rmdopen-2017-000584","article-title":"Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study","volume":"4","author":"Fleischmann","year":"2018","journal-title":"RMD Open"},{"key":"key\n\t\t\t\t20180823035348_key100-B28","doi-asserted-by":"crossref","first-page":"e000647","DOI":"10.1136\/rmdopen-2017-000584","article-title":"Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study","volume":"4","author":"Fleischmann","year":"2018","journal-title":"RMD Open"},{"key":"key\n\t\t\t\t20180823035348_key100-B29","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3899\/jrheum.101156","article-title":"Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors","volume":"38","author":"Goldfarb","year":"2011","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180823035348_key100-B30","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1440-1797.2010.01368.x","article-title":"Interactions of urate transporter URAT1 in human kidney with uricosuric drugs","volume":"16","author":"Shin","year":"2011","journal-title":"Nephrology"},{"key":"key\n\t\t\t\t20180823035348_key100-B31","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.1119","article-title":"Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad (RDEA3170) and Allopurinol in Male Subjects With Gout","author":"Kankam","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180823035348_key100-B32","article-title":"Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers","author":"Hall","year":"2018","journal-title":"J Clin Pharmcol"},{"key":"key\n\t\t\t\t20180823035348_key100-B33","first-page":"1401","article-title":"Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0","volume":"34","author":"Woodworth","year":"2007","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180823035348_key100-B34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12018-011-9106-6","article-title":"Uric acid nephrolithiasis: a systemic metabolic disorder","volume":"9","author":"Wiederkehr","year":"2011","journal-title":"Clin Rev Bone Miner Metab"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/57\/9\/1602\/25518836\/key100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T01:41:10Z","timestamp":1571103670000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/57\/9\/1602\/5032321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,6,1]]},"published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key100","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9]]},"published":{"date-parts":[[2018,6,1]]}}}